List of Excipients in Branded Drug ZEPBOUND

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	ZEPBOUND	tirzepatide	0002-2506	HYDROCHLORIC ACID	2027-12-20
Eli Lilly and Company	ZEPBOUND	tirzepatide	0002-2506	SODIUM CHLORIDE	2027-12-20
Eli Lilly and Company	ZEPBOUND	tirzepatide	0002-2506	SODIUM HYDROXIDE	2027-12-20
Eli Lilly and Company	ZEPBOUND	tirzepatide	0002-2506	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE	2027-12-20
Eli Lilly and Company	ZEPBOUND	tirzepatide	0002-2506	WATER	2027-12-20

Zepbound Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Zepbound is Eli Lilly’s tirzepatide injection for chronic weight management. Its commercial excipient strategy is deliberately simple: an aqueous, sterile, preservative-free peptide formulation using sodium chloride, sodium phosphate dibasic heptahydrate, and Water for Injection, with pH adjustment as needed. The opportunity for excipient suppliers is therefore concentrated in supply security, injectable-grade quality, container-closure compatibility, device performance, manufacturing capacity, and differentiated next-generation formulations rather than in selling a complex proprietary excipient system. [1]

What excipients are used in Zepbound?

The U.S. Zepbound prescribing information identifies the inactive ingredients as sodium chloride, sodium phosphate dibasic heptahydrate, and Water for Injection. Hydrochloric acid and sodium hydroxide may be used for pH adjustment. The product is a sterile, clear, colorless to slightly yellow solution supplied for subcutaneous administration. [1]

Formulation characteristic	Zepbound profile
Active ingredient	Tirzepatide
Dosage form	Sterile injectable solution
Route	Subcutaneous
Preservative	None identified in the U.S. label
Buffer	Sodium phosphate dibasic heptahydrate
Tonicity agent	Sodium chloride
Vehicle	Water for Injection
pH control	Hydrochloric acid and sodium hydroxide, as needed
U.S. strengths	2.5, 5, 7.5, 10, 12.5, and 15 mg per 0.5 mL
Manufacturer	Eli Lilly and Company
Delivery systems	Single-dose prefilled pen and single-dose vial presentations, subject to market and label updates

The formulation uses a conventional parenteral platform. This reduces formulation complexity but increases the importance of raw-material control, particulate limits, endotoxin performance, sterility assurance, fill-finish reliability, and compatibility with the injection device.

Why does Zepbound use a simple excipient system?

Tirzepatide is a large synthetic peptide with a fatty-acid-containing structure designed to extend circulation time through albumin binding. The active ingredient does not require a conventional oral solubilizer system because Zepbound is administered subcutaneously. [1,2]

A simple aqueous formulation can provide several advantages:

1. Lower excipient burden.
2. Reduced risk of excipient-related immunogenicity or intolerance.
3. Simplified regulatory characterization.
4. Easier scale-up across vial and pen presentations.
5. Lower formulation cost per dose.
6. Greater flexibility in global manufacturing and fill-finish operations.

The tradeoff is that the commercial value shifts away from novel excipient composition and toward process control, stability, packaging, and delivery technology.

What commercial opportunities exist for Zepbound excipient suppliers?

The largest opportunities are in qualified supply and manufacturing performance rather than a new excipient molecule.

Injectable-grade sodium chloride and phosphate buffer

Sodium chloride and sodium phosphate dibasic heptahydrate are commodity materials in chemical terms but regulated inputs in a high-volume sterile injectable product. Suppliers must support:

• Compendial compliance.
• Tight impurity specifications.
• Low bioburden and endotoxin control.
• Lot-to-lot consistency.
• Validated sterilization or sterile filtration compatibility.
• Long-term supply agreements.
• Dual-site or regional manufacturing capacity.

Zepbound’s growth increases demand for reliable supply of both materials. The commercial value of a supplier relationship depends less on unit price than on qualification status, change-control discipline, capacity reservation, and the ability to support a high-throughput sterile manufacturing network.

Water for Injection

Water for Injection is not a differentiated formulation excipient, but it is a critical manufacturing input. Opportunities exist for engineering and operating systems that provide:

• Continuous microbial control.
• Low total organic carbon.
• Low endotoxin levels.
• Stable quality during high-volume production.
• Reduced energy and water consumption.
• Validated storage and distribution loops.

For a high-demand injectable such as Zepbound, WFI capacity can become a manufacturing constraint even when the chemical excipients are readily available.

Container-closure systems

The drug product is delivered through pen and vial formats. Container-closure suppliers can compete through systems that minimize:

• Peptide adsorption.
• Silicone oil interaction.
• Extractables and leachables.
• Particulate generation.
• Needle penetration force.
• Stopper coring.
• Headspace-related oxidation or degradation.
• Dose-volume variability.

The relevant commercial products include glass cartridges, elastomeric stoppers, plungers, needle shields, syringes, pen assemblies, and primary packaging coatings. These components may be protected through device, material, manufacturing, and combination-product patents even when the underlying excipients are generic.

Fill-finish and device assembly

Contract manufacturing organizations with sterile fill-finish capacity can benefit from demand for tirzepatide products, although Eli Lilly has invested heavily in internal and external capacity. Attractive capabilities include:

• High-speed aseptic filling.
• Low-volume peptide filling.
• Automated visual inspection.
• Pen assembly.
• Vial labeling and serialization.
• Cold-chain distribution.
• Flexible batch sizes for multiple strengths.
• Technology transfer under strict change control.

The best-positioned suppliers are those already qualified for complex sterile injectables and combination products. A new supplier faces long validation cycles and may not displace an incumbent without a capacity, cost, or technical advantage.

What formulation patents protect Zepbound?

The core commercial protection for Zepbound is expected to center on tirzepatide composition-of-matter rights, manufacturing processes, therapeutic uses, formulations, and delivery systems. The existence and enforceability of a patent do not depend on whether a formulation uses novel excipients.

A basic sodium chloride/phosphate/WFI formulation is unlikely to provide a strong standalone exclusivity position if the composition is obvious and conventional. Stronger protection may arise from:

• Specific tirzepatide formulations with defined pH or concentration ranges.
• Stabilized peptide formulations.
• Low-degradation formulations.
• Particular container-closure combinations.
• Pen and autoinjector designs.
• Manufacturing and purification processes.
• Dosing regimens for obesity or related comorbidities.
• Combination therapy involving tirzepatide.

The U.S. Food and Drug Administration’s Orange Book should be reviewed for current listed patents covering Zepbound. Orange Book listings can change through patent-listing updates, delistings, corrections, and litigation outcomes. [3]

How strong is the Zepbound patent estate?

The strongest protection is generally expected to come from the active pharmaceutical ingredient and related use claims, not from sodium chloride or phosphate. A formulation-only challenge could still be commercially important if a competitor develops a distinct stable formulation that avoids claimed ranges and formulation limitations.

Patent strength depends on:

Patent category	Commercial importance
Tirzepatide composition claims	Very high
Peptide synthesis and purification	High
Obesity treatment methods	High
Diabetes and metabolic disease methods	High
Specific formulation ranges	Medium to high
Device and delivery system claims	Medium to high
Sodium chloride/phosphate composition alone	Low
Packaging and container-closure claims	Medium

When does Zepbound lose exclusivity?

Zepbound’s loss of exclusivity will depend on the expiration of applicable composition, formulation, use, and manufacturing patents, as well as FDA regulatory exclusivity.

Eli Lilly disclosed extensive patent protection for tirzepatide and related products in its public filings. The principal composition-of-matter protection is expected to extend into the 2030s, although the effective commercial exclusivity period may be affected by patent-term adjustment, patent-term extension, pediatric exclusivity, litigation, settlements, and the scope of approved claims. [2,4]

Exclusivity element	Zepbound implication
FDA approval	November 2023 for chronic weight management
New chemical entity exclusivity	Five years from approval, subject to statutory exceptions
Composition patents	Expected to be the primary barrier to early generic entry
Method-of-use patents	May delay or complicate obesity-indication substitution
Formulation patents	Could protect specific product presentations
Device patents	May limit direct pen copying but not necessarily vial entry
Patent-term extension	Possible, but not assumed without a confirmed regulatory record
Biosimilar pathway	Not the principal pathway for this synthetic peptide

A precise loss-of-exclusivity date requires the current Orange Book record, issued patent data, patent-term calculations, and any applicable pediatric or regulatory extensions. Those dates should not be inferred from the five-year new chemical entity period alone.

Are generic companies challenging Zepbound patents?

A generic company seeking tirzepatide approval could pursue an abbreviated new drug application if the product and legal pathway satisfy FDA requirements. Because tirzepatide is a synthetic peptide rather than a conventional small molecule, product characterization, sameness, manufacturing complexity, and FDA pathway strategy may be more demanding than for a typical tablet.

Potential challengers could use:

• Paragraph IV certifications against listed patents.
• Section viii statements that carve out patented methods of use.
• A 505(b)(2) application for a differentiated formulation or delivery system.
• A full new drug application if the product cannot qualify for an abbreviated route.
• A vial product that avoids pen-device claims.
• A formulation that differs in excipient composition, concentration, or packaging.

Paragraph IV litigation risk is highest when a challenger believes it can invalidate or design around composition, formulation, or method-of-use patents before their expiry. A public challenge is only commercially meaningful once an ANDA or related application has been filed and litigation or FDA review has been triggered.

What is the FDA regulatory status of Zepbound?

FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition, in combination with reduced-calorie diet and increased physical activity. Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity, based on a later supplemental approval. [1,5]

The regulatory profile matters for excipient strategy because each new indication can expand demand without requiring a new excipient platform. It also increases the value of manufacturing capacity and supply continuity.

The product is a prescription injectable and is not a biosimilar. Tirzepatide is a peptide drug with biologic-like manufacturing and analytical considerations, but Zepbound does not enter the market through the standard interchangeable biosimilar framework used for many therapeutic proteins.

What biosimilar and generic risks exist for Zepbound?

The immediate competitive threat is more likely to come from other incretin therapies, authorized products, compounded products, or later generic-style tirzepatide products than from biosimilars.

Key risks include:

• A competing tirzepatide product with a vial presentation.
• A lower-cost product that avoids pen-device claims.
• A 505(b)(2) product using a different excipient system.
• Compounded tirzepatide during legally recognized shortage conditions.
• Competing GLP-1 or GLP-1/GIP products from Novo Nordisk and other developers.
• New oral or long-acting formulations that improve convenience.

For excipient companies, this competitive environment creates two market paths. The first is supplying Lilly’s established formulation and manufacturing network. The second is supporting alternative tirzepatide products with improved stability, higher concentration, longer storage, reduced injection volume, or different delivery systems.

How does Zepbound compare with competing GLP-1 products?

Zepbound competes primarily with Wegovy, Saxenda, Ozempic used off-label for weight management, and emerging incretin products. Its active ingredient and formulation platform differ from semaglutide and liraglutide products.

Product	Active ingredient	Primary formulation opportunity
Zepbound	Tirzepatide	Aqueous peptide injection, pen and vial systems
Wegovy	Semaglutide	Aqueous peptide injection, pen system
Saxenda	Liraglutide	Aqueous peptide injection, multi-dose pen
Ozempic	Semaglutide	Aqueous peptide injection, multi-dose pen
Oral incretin candidates	Various	Solubilization, permeability enhancement, enteric or controlled-release systems

Zepbound’s simple excipient platform limits differentiation through conventional formulation chemistry. Competitive differentiation is more likely through dose escalation, injection volume, device ergonomics, storage conditions, manufacturing yield, and future oral or long-acting delivery systems.

What licensing opportunities exist around Zepbound excipients?

Direct licensing of sodium chloride or sodium phosphate technology is unlikely to be the central opportunity. More valuable licensing targets include:

• Proprietary peptide stabilization systems.
• High-concentration tirzepatide formulations.
• Sustained-release injectable depots.
• Long-acting microspheres or implants.
• Low-volume injection systems.
• Pen and autoinjector platforms.
• Silicone-free or low-silicone primary containers.
• Anti-adsorption coatings.
• Lyophilized tirzepatide presentations.
• Oral delivery technologies.
• Manufacturing processes that improve yield or reduce aggregation.

Lilly’s licensing and business-development strategy is more likely to focus on delivery platforms, manufacturing technologies, indications, and combination products than on conventional excipients already identified in the approved formulation. Public Lilly filings identify product and pipeline collaborations, but a definitive Zepbound-specific excipient license should not be assumed without a disclosed agreement. [2]

What manufacturing and intellectual-property barriers affect excipient suppliers?

The main barriers are qualification and scale.

An excipient supplier must demonstrate that its material does not alter tirzepatide potency, purity, aggregation, degradation profile, sterility, or device performance. A seemingly minor change in supplier, manufacturing site, particle characteristics, hydration state, packaging, or impurity profile may require comparability work and regulatory reporting.

The most defensible supplier positions combine:

1. Approved or qualified material status.
2. Capacity reserved for commercial production.
3. Multiple manufacturing sites.
4. Strong change-control history.
5. Low extractables and leachables risk.
6. Sterile injectable quality systems.
7. Technical support during regulatory submissions.
8. Long-term supply contracts.

The commercial moat is therefore operational and regulatory. A supplier offering the same chemical identity at a lower price may still fail to displace an incumbent if the switching cost includes process validation, stability studies, container-closure testing, and regulatory approval.

What generic launch scenarios are most plausible?

Three launch scenarios are commercially relevant.

Vial-first entry

A challenger could target a vial presentation and avoid some pen-device patents. This strategy may reduce device complexity but would compete on usability, packaging, manufacturing capacity, and reimbursement.

Formulation design-around

A challenger could modify buffer, tonicity agent, concentration, or container system while preserving tirzepatide as the active ingredient. The principal risks would be stability, injectability, immunogenicity, bioequivalence, and patent claim scope.

Post-patent broad competition

After core composition and use patents expire, multiple manufacturers could enter with conventional aqueous formulations. At that stage, excipient cost, fill-finish yield, device pricing, and supply reliability would become more important than formulation differentiation.

Key Takeaways

• Zepbound uses a simple sterile aqueous formulation based on sodium chloride, sodium phosphate dibasic heptahydrate, and Water for Injection.
• The principal excipient opportunity is qualified supply, not a novel excipient composition.
• High-value commercial opportunities include WFI systems, sterile fill-finish, primary packaging, pen components, elastomeric closures, and peptide-compatible container systems.
• Zepbound’s strongest exclusivity is expected to come from tirzepatide composition, manufacturing, therapeutic-use, formulation, and device patents.
• Generic competition may use Paragraph IV litigation, a 505(b)(2) strategy, a vial presentation, or a formulation design-around.
• Zepbound is not a biosimilar product, and biosimilar substitution is not the principal competitive pathway.
• Future value is likely to shift toward high-concentration, low-volume, long-acting, oral, or otherwise differentiated tirzepatide delivery systems.
• Excipient suppliers with regulatory qualification, redundant capacity, and strong change-control systems have the clearest commercial position.

FAQs About Zepbound Excipient Strategy

Does Zepbound contain polysorbate 80?

The U.S. prescribing information identifies sodium chloride, sodium phosphate dibasic heptahydrate, and Water for Injection as inactive ingredients. Polysorbate 80 is not listed in that formulation. [1]

Is Zepbound a lyophilized peptide drug?

No. The U.S. product is supplied as a ready-to-use sterile injectable solution rather than a lyophilized powder requiring reconstitution. [1]

Can a generic manufacturer copy Zepbound’s excipients?

A manufacturer may be able to use the same excipients if it meets applicable regulatory requirements and does not infringe valid patent claims. Matching the excipients does not by itself establish pharmaceutical equivalence, bioequivalence, stability, device compatibility, or freedom to operate.

Which excipient is most important for Zepbound stability?

The buffer system, pH control, container-closure system, and manufacturing conditions collectively influence peptide stability. The FDA label does not identify one excipient as the sole stability determinant.

Could a higher-concentration Zepbound formulation reduce excipient demand?

Yes. A higher-concentration or lower-volume product could reduce excipient use per dose, although total demand could still rise with patient growth. Such a product would require separate formulation, device, stability, manufacturing, and regulatory validation.

References

1. U.S. Food and Drug Administration. (2024). Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.

2. Eli Lilly and Company. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

4. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources.

5. U.S. Food and Drug Administration. (2024). FDA approves first medication for obstructive sleep apnea in adults with obesity.